THE MCMANUS GROUP for GILEAD SCIENCES, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to reforming and increasing transparency within the 340B Drug Pricing Program including in H.R. 3290 - To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. Issues related to commercial delinking of PBMs - H.R.6283/S.1542 - DRUG Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Medicare/Medicaid MMM
Access and reimbursement of drugs in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R.5378 - Lower Costs, More Transparency Act Issues related to Part D delinking of PBMs in H.R.2880 - Protecting Patients Against PBM Abuses Act, S.1967 - PBM Act, S. 2973 - The Modernizing and Ensuring PBM Accountability (MEPA) Act, H.R.8261 - Preserving Telehealth, Hospital, and Ambulance Access Act S.3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 H.R.5547/S. 476- MINI Act S.2764/H.R.5391 - Protecting Patient Access to Cancer and Complex Therapies Act of 2023 S.3131 - ORPHAN Cures Act, H.R.5539 - Optimizing Research Progress Hope and New Cures Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.